sitimagene ceradenovec
AXP000147.1 · Viral vector gene therapy
- Platform
- adenovirus (Ad5, E1-deleted, HSV-TK)
- Originator
- Ark Therapeutics
- Sponsor
- Ark Therapeutics
Names
| Name | Type | Source |
|---|---|---|
| sitimagene ceradenovec | preferred name, INN | curator, ncit |
| Cerepro | brand | press |
| EG-009 ambiguous | code | ncit |
Virus
- Role
- In vivo gene transfer
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5
- Replication
- non replicating
- Modifications
- E1-deleted adenoviral vector encoding HSV thymidine kinase; given with intravenous ganciclovir
- Transgenes
- HSV-TK
- Route
- intracerebral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C162553
Approvals
No regulatory approval recorded.
Clinical trials (0)
No trial in the latest ClinicalTrials.gov snapshot names this program.
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 34710575 | Are Two-Dimensional Morphometric Measures Reflective of Disease Severity in Adult Chiari I Malformation? | World neurosurgery | 2022 | name in abstract: Cerepro |
| PMID 23850491 | Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. | The Lancet. Oncology | 2013 | name in title: sitimagene ceradenovec |
| PMID 22677751 | [The use of cerepro (choline alfoscerate) in the treatment of outpatients with chronic progressive cerebrovascular disease]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova | 2012 | name in title: Cerepro |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 36511461 | [Physical factors in the medical rehabilitation of patients with chronic cerebral ischemia in the outpatient stage]. | Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury | 2022 | name in abstract: Cerepro |
| PMID 28560211 | Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe. | Frontiers in medicine | 2017 | name in abstract: Cerepro |
| PMID 26052534 | Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera. | Molecular therapy. Methods & clinical development | 2015 | name in abstract: Cerepro |
| PMID 24352098 | Potential new gene therapy option with sitimagene ceradenovec for newly diagnosed patients with glioblastoma multiforme. | Cancer biology & therapy | 2014 | name in title: sitimagene ceradenovec |
| PMID 21142657 | Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma. | Future oncology (London, England) | 2010 | name in title: sitimagene ceradenovec |
| PMID 19367582 | A preclinical assessment of the safety and biodistribution of an adenoviral vector containing the herpes simplex virus thymidine kinase gene (Cerepro) after intracerebral administration. | The journal of gene medicine | 2009 | name in title: Cerepro |
| PMID 18386231 | Sitimagene ceradenovec, a gene therapeutic for the treatment of glioma. | Current opinion in molecular therapeutics | 2008 | name in title: sitimagene ceradenovec |
| PMID 20021420 | Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications. | Current molecular pharmacology | 2008 | name in abstract: Cerepro |
| PMID 18477977 | [The experience of the use of cerepro in the treatment of out-patients in the early period of rehabilitation of is ischemic stroke.]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova | 2007 | name in title: Cerepro |
Notes
Cerepro: adenoviral HSV thymidine kinase injected into the wall of the resection cavity after surgery for high-grade glioma, followed by intravenous ganciclovir. The CHMP adopted a negative opinion and Ark withdrew the EU application on 8 March 2010 during re-examination; never approved. EG-009 is the development code.
How to cite
sitimagene ceradenovec (AXP000147.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000147.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.